Pang Phillip 4
4 · Vir Biotechnology, Inc. · Filed Jan 25, 2023
Insider Transaction Report
Form 4
Pang Phillip
Chief Medical Officer
Transactions
- Award
Common Stock
2023-01-24$5.17/sh+4,594$23,774→ 174,000 total - Award
Common Stock
2023-01-24$1.57/sh+25,406$40,014→ 169,406 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-01-24−4,594→ 37,535 totalExercise: $5.17Exp: 2029-03-11→ Common Stock (4,594 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2023-01-24−25,406→ 13,576 totalExercise: $1.57Exp: 2028-07-19→ Common Stock (25,406 underlying) - Sale
Common Stock
2023-01-24$30.00/sh−30,000$900,057→ 144,000 total
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F4]1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.